单位：[1]Beijing Key Lab for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China[2]Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China[3]College of Pharmacy, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
Aim: The aim of this study was to investigate the potential of a recombinant vaccine encoding TGF-beta 1 in OLETF rats with diabetic nephropathy (DN). Methods: OLETF rats were treated with vehicle or TGF-beta 1 vaccine. LETO rats were used as normal controls. At 42 weeks after immunization with vaccine, samples from blood, urine and kidney were collected for biochemical, histologic, immunohistochemical and molecular analyses. Results: OLETF rats treated with the vaccine reduced blood glucose levels, improved renal pathological changes, and inhibited overexpression of TGF-beta 1 and p-Smad3, as well as MCP-1, TNF-alpha and IL-1 beta. Conclusion: TGF-beta 1 vaccine attenuated diabetic nephropathy in OLETF rats through reduction of inflammation, improvement of kidney fibrosis and partial correction of glucose metabolism.
基金：
Project of International Collaboration in Science and Technology Grant, China [2011DFA31860]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81173422, 81373795, 81302942, 81473526]
第一作者单位：[1]Beijing Key Lab for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
